The U.S. chronic wound care market was valued at USD 4.43 billion in 2023 and is projected to grow at a CAGR of 6.8% through 2032. The market covers wound types including diabetic foot ulcers, pressure ulcers, venous leg ulcers, and associated care products ranging from advanced dressings to active therapies.
Chronic wounds affect an estimated 6.5 million people in the U.S. annually, according to the American Academy of Home Care Medicine. This substantial patient base, combined with an aging population and rising chronic disease burden, forms the foundation of steady market growth.
Key Growth Drivers
Rising Prevalence of Chronic Diseases Diabetes, systemic illness, and circulatory disorders significantly increase the risk of developing hard-to-heal wounds. According to the National Diabetes Statistics Report 2022, approximately 37.3 million Americans had diabetes. Among diabetic patients, roughly 5% develop diabetic foot ulcers, and 1% ultimately require amputation. The lifetime risk of developing foot ulcers among diabetic individuals ranges between 19% and 34%.
Aging Population Elderly individuals are more prone to chronic wounds due to limited mobility, making pressure ulcers a major concern. The Administration for Community Living reported around 54.1 million Americans aged 65 and above in 2019, a figure projected to reach 80.8 million by 2040. Pressure ulcers alone affect between 1 million and 3 million Americans annually.
Awareness and Product Innovation Government agencies and private companies are actively promoting early diagnosis and wound management. In January 2022, Healogics launched the "Healing Can't Wait" campaign to raise awareness about chronic wounds and the importance of timely intervention. Alongside awareness, increasing new product approvals are further accelerating market adoption.
More Details: https://www.fortunebusinessinsights.com/u-s-chronic-wound-care-market-108085
Market Trends
Shift Toward Active Therapy A growing preference for bioactive therapies is reshaping treatment protocols. These therapies prevent tissue dehydration and accelerate healing, making them especially effective for chronic wounds. Manufacturers are investing heavily in R&D — for instance, Michigan State University researchers began developing biopolymer-based wound dressings for diabetic foot ulcers in 2021.
Market Segmentation
By Type Diabetic foot ulcers hold the largest market share among wound types, driven by the high prevalence of uncontrolled diabetes and a strong pipeline of targeted products. Pressure ulcers and venous leg ulcers are also significant segments.
By Product Advanced wound dressings dominate due to their cost-effectiveness and clinical efficiency. The 2019 FDA clearance of Advanced Medical Solutions' silicone PHMB foam and silver antimicrobial dressings illustrates the ongoing innovation in this category. Wound care devices and active therapies are growing segments.
By End User Hospitals and wound clinics currently lead market share, but the homecare settings segment is expected to witness the fastest growth. The rising preference among elderly patients for home-based treatment is pushing manufacturers to develop user-friendly products. Medela AG's 2022 FDA-approved Invia Ease NPWT System, designed for both acute and homecare use, reflects this shift.
Restraining Factors
Despite positive momentum, product recalls pose a significant challenge. In June 2020, the FDA initiated a Class II recall for KCI USA's ACTIV.A.C Therapy System due to power supply malfunctions affecting NPWT delivery. The stringent Class II medical device approval process and rising recall incidents limit faster market penetration.
Competitive Landscape
The market is consolidated, with a few large players commanding dominant positions:
- 3M (U.S.)
- Smith & Nephew (U.K.)
- ConvaTec Group PLC (U.K.)
- Mölnlycke Health Care AB (Sweden)
- Integra LifeSciences Corporation (U.S.)
- B. Braun Melsungen AG (Germany)
- Coloplast Corp (Denmark)
- Cardinal Health (U.S.)
- MiMedx (U.S.)
- Tissue Regenix (U.S.)
Recent key developments include ConvaTec's January 2023 launch of ConvaFoam with super absorber technology, its 2022 acquisition of Triad LifeSciences to enter wound biologics, and the November 2022 formation of SI Wound Care LLC through an InfuSystem–Sanara MedTech partnership focused on low-cost NPWT solutions.